MASH Clinical reposted this
During the 2024 𝐄𝐀𝐒 𝐚𝐧𝐝 𝐄𝐀𝐒𝐋 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬𝐞𝐬, our talented researchers have made notable contributions by presenting their posters Alina Saidi presented "𝐋𝐢𝐯𝐞𝐫 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐞𝐬 𝐎𝐛𝐞𝐬𝐞 𝐒𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐚𝐭 𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐑𝐢𝐬𝐤 𝐟𝐨𝐫 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: 𝐓𝐡𝐞 𝐀𝐬𝐬𝐢𝐬𝐢 𝐒𝐭𝐮𝐝𝐲." Her research emphasizes liver fibrosis as a crucial marker for cardiovascular risk in obese individuals, providing valuable insights for early intervention and management. Willy Theel MSc presented: "𝐄𝐟𝐟𝐞𝐜𝐭 𝐨𝐟 𝐏𝐫𝐚𝐯𝐚𝐬𝐭𝐚𝐭𝐢𝐧 𝐨𝐧 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐢𝐧 𝐚𝐧 𝐄𝐥𝐝𝐞𝐫𝐥𝐲 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐚𝐧𝐝 𝐋𝐢𝐯𝐞𝐫 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬." His work was not only highly recognized but also selected as a top-rated poster presentation, underscoring its importance. His findings explore the potential benefits of pravastatin in reducing cardiovascular risks among elderly patients with obesity and liver fibrosis. For a detailed look at the presented posters, visit the MASH Clinical website: https://lnkd.in/d_QAH32A
